Search Grant Opportunities

Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)

ID: RFA-TR-20-003 • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Who is eligible to apply for this grant?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Overview

Category of Funding
Health
Funding Instruments
Cooperative Agreement
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 8/5/20 the National Institutes of Health posted grant opportunity RFA-TR-20-003 for Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required). The grant will be issued under grant program 93.350 National Center for Advancing Translational Sciences.

Timing

Posted Date
Aug. 5, 2020, 12:00 a.m. EDT
Closing Date
Jan. 23, 2021, 12:00 a.m. EST Past Due
Last Updated
Aug. 5, 2020, 3:29 p.m. EDT
Version
1
Archive Date
Feb. 28, 2021

Eligibility

Eligible Applicants
County governments
Special district governments
Small businesses
State governments
City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
For profit organizations other than small businesses
Independent school districts
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Info
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Award Sizing

Ceiling
$3,000,000
Floor
Not Listed
Estimated Program Funding
Not Provided
Estimated Number of Grants
Not Listed

Contacts

Contact
National Institutes of Health
Contact Email
Email Description
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Contact Phone
(301) 402-2541

Documents

Posted documents for RFA-TR-20-003

Grant Awards

Grants awarded through RFA-TR-20-003

Incumbent or Similar Grants

Similar Active Opportunities

Open grant opportunities similar to RFA-TR-20-003

Experts for Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)

Recommended subject matter experts available for hire